Although PD-L1 expression in tumor cells guides the use of anti-PD-1/PD-L1 in NSCLC and other cancers, its role as a biomarker is controversial due to its dynamic nature and limited predictive accuracy [43]. This evidence concerns the gene CD274 and neoplasm.